Media Inquiries

If you are interested in interviewing a CCR scientist, OR you are a scientist who has been contacted by a member of the media, please contact the NCI Press Office at ncipressofficers@mail.nih.gov or by phone at 240.760.6600.

News and Events

Cellular processing reverses molecule’s effect on anticancer immunity

Immune cells convert an immunosuppressive lipid into an anticancer immunity enhancer.

Howard A. Young, Ph.D., cutting the ribbon to celebrate the opening of his lab in the 1980s.

Celebrating CCR Careers: Howard A. Young, Ph.D.

Howard A. Young, Ph.D., spent over 40 years researching cytokine gene expression, especially interferons and how they contribute to chronic inflammation and disease. Now, he has announced his retirement.

Clinical trial researching neuroendocrine neoplasms

A clinical trial led by Jaydira Del Rivero, M.D., Associate Research Physician in the Developmental Therapeutics Branch, is researching the biology of neuroendocrine neoplasms.

Clinical trial researching therapy for neuroendocrine cancer

A clinical trial led by Jaydira Del Rivero, M.D., Associate Research Physician in the Developmental Therapeutics Branch, is researching a combination drug therapy for neuroendocrine cancer.

Aligned Blog: Access in Appalachia

For people living in rural areas, access to healthcare can be a challenge. In this latest issue of Aligned, CCR Social Media Strategist Jenna Pierson writes about the experience of those living in Appalachia as they navigate healthcare and what is being done to address disparities in access to care for rural communities.

Celebrating CCR Careers: William G. Stetler-Stevenson, M.D., Ph.D.

For over three decades, William G. Stetler-Stevenson, M.D., Ph.D., has been a leader in the field of tissue inhibitors of metalloproteinases (TIMP) biology and extracellular matrix regulation of cancer.

Celebrating CCR Careers: Allan M. Weissman, M.D.

Allan M. Weissman, M.D., who explored the essential underpinning of ubiquitin in cancer, announces his retirement from the NCI.

Celebrating CCR Careers: Kathleen Kelly, Ph.D.

Kathleen Kelly, Ph.D., who pioneered new frameworks for modeling and exploring how prostate cancer cells respond to anti-cancer drugs, announces her retirement from the NCI.

PROTACtion against resistance of commonly used anti-cancer drug

Drugs known as PIM kinase inhibitors are used to treat a range of cancers, but many patients develop resistance to these medications. Recent research has led to a new class of therapeutics that target the mechanism of this resistance, resulting in increased death of cancer cells.

Celebrating CCR Careers: Kenneth H. Kraemer, M.D.

For more than fifty years, Kenneth H. Kraemer, M.D., has investigated the molecular underpinnings and clinical manifestations of xeroderma pigmentosum, a rare disease that makes children highly vulnerable to skin damage and cancers from ultraviolet radiation, at the NCI.

Molecular signature can identify tumor-targeting immune cells in the blood

Blood samples could be a new source of antitumor T cells for customized cancer immunotherapies.

Breadcrumb

News and Events